Recent advances in mantle cell lymphoma: Report of the 2013 Mantle Cell Lymphoma Consortium Workshop

Leo I. Gordon, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas Elmer Witzig, Martin Dreyling

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

Original languageEnglish (US)
Pages (from-to)2262-2270
Number of pages9
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Mantle-Cell Lymphoma
Education
Lymphoma
Genetic Translocation
Cyclin D1
B-Cell Lymphoma
Standard of Care
Non-Hodgkin's Lymphoma
Therapeutics
Biomarkers
Research

Keywords

  • Immunotherapy
  • Lymphoma and Hodgkin disease
  • Marrow and stem cell transplant clinical results
  • Pharmacotherapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Recent advances in mantle cell lymphoma : Report of the 2013 Mantle Cell Lymphoma Consortium Workshop. / Gordon, Leo I.; Bernstein, Steven H.; Jares, Pedro; Kahl, Brad S.; Witzig, Thomas Elmer; Dreyling, Martin.

In: Leukemia and Lymphoma, Vol. 55, No. 10, 01.10.2014, p. 2262-2270.

Research output: Contribution to journalArticle

Gordon, Leo I. ; Bernstein, Steven H. ; Jares, Pedro ; Kahl, Brad S. ; Witzig, Thomas Elmer ; Dreyling, Martin. / Recent advances in mantle cell lymphoma : Report of the 2013 Mantle Cell Lymphoma Consortium Workshop. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 10. pp. 2262-2270.
@article{5864c0d7134948d98c68fb249914d96d,
title = "Recent advances in mantle cell lymphoma: Report of the 2013 Mantle Cell Lymphoma Consortium Workshop",
abstract = "Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.",
keywords = "Immunotherapy, Lymphoma and Hodgkin disease, Marrow and stem cell transplant clinical results, Pharmacotherapeutics",
author = "Gordon, {Leo I.} and Bernstein, {Steven H.} and Pedro Jares and Kahl, {Brad S.} and Witzig, {Thomas Elmer} and Martin Dreyling",
year = "2014",
month = "10",
day = "1",
doi = "10.3109/10428194.2013.876634",
language = "English (US)",
volume = "55",
pages = "2262--2270",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Recent advances in mantle cell lymphoma

T2 - Report of the 2013 Mantle Cell Lymphoma Consortium Workshop

AU - Gordon, Leo I.

AU - Bernstein, Steven H.

AU - Jares, Pedro

AU - Kahl, Brad S.

AU - Witzig, Thomas Elmer

AU - Dreyling, Martin

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

AB - Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by overexpression of cyclin D1 resulting from the t(11;14) chromosomal translocation. MCL is biologically and clinically heterogeneous and frequently disseminates to extranodal areas. MCL remains a clinically challenging lymphoma subtype, as there is no proven curative therapy and no standard of care has been established for initial or subsequent lines of therapy. However, there have been considerable advances in the last several years in the treatment of MCL, leading to improved survival. Recent investigations into the biology of MCL, clinically relevant biomarkers, novel therapeutic targets and new treatment strategies were discussed at a recent workshop of the Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium. The presentations are summarized in this manuscript, which is intended to highlight areas of active investigation and identify topics for future research.

KW - Immunotherapy

KW - Lymphoma and Hodgkin disease

KW - Marrow and stem cell transplant clinical results

KW - Pharmacotherapeutics

UR - http://www.scopus.com/inward/record.url?scp=84925294622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925294622&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.876634

DO - 10.3109/10428194.2013.876634

M3 - Article

C2 - 24512319

AN - SCOPUS:84925294622

VL - 55

SP - 2262

EP - 2270

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -